ASCO® 2026 Highlights: Presenter Vignette – Scott Kopetz
Scott Kopetz
MD, PhD, FASCO
MD Anderson Cancer Center
LBA3503
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).